Acasti Pharma Inc., an emerging biopharmaceutical company, announces top-line results for its pharmacokinetic trial evaluating the bioavailability and safety of CaPre on healthy individuals taking single and multiple daily oral doses of the Corporation's new investigational drug candidate composed of a patent-protected highly concentrated...
Dr Mulkerrin has more than 20 years of industry experience in biologics manufacturing, most recently as Vice President, Process Development and Manufacturing at OncoMed and has had prior senior roles at Abgenix, Amgen and Genentech. Dr Simon Chivers joins as Head of Toxicology. Dr. Chivers has more than 15 years of industry experience, most recentl
In the interview posted online since September 15, Pharma IQ asked Dr. Sherley to respond to several questions on the current state of technologies for evaluating stem cell toxicity, challenges to evaluating stem cell toxicity, and future trends in the use of stem cells for toxicological drug evaluations. Dr. Sherley was invited to lead the session
BEDMINSTER, N.J.& RESEARCH TRIANGLE PARK, N.C.& NEWPORT BEACH, Calif. Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, announced today that it has closed its $125 million financing with Deerfield Management Company L.P., a curre
Akorn, Inc., a niche pharmaceutical company, today announced that it has signed a definitive agreement to acquire certain rights to short-acting bronchodilator Xopenex Inhalation Solution from Sunovion Pharmaceuticals Inc. for $45 million, paid in cash at closing, net of certain liabilities. "We are excited to announce this transaction which
Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that it has received a $25 million advance from Hercules Technology Growth Capital, Inc.. The payment is the second and final advance under the Loan and Security Agreement
"We are so pleased to be joining the Janssen Pharmaceutical Companies of Johnson& Johnson, who have an impressive track record of bringing breakthrough drugs for viral diseases to market," said Lawrence M. Blatt, PhD, President and Chief Executive Officer of Alios BioPharma. Goldman, Sachs& Co. acted as exclusive financial advisor to Alios BioPharm
Amicus Therapeutics today announced that Bradley Campbell, Chief Operating Officer and Chip Baird, Chief Financial Officer, will present a corporate overview at the Leerink Partners Rare Disease Roundtable in New York, NY on Wednesday, October 1, 2014 at 8:50 a.m. ET. A live webcast of the presentation can be accessed through the Investors sectio
The very act of suggesting or announcing a potential cure for the dreaded Ebola Virus Disease, EVD, has become riskier than envisaged as claimants of such unverified and "unorthodox" cures now stand the risk of going to prison if threats by the American Food and Drug Administration, FDA, are anything to go by. Just last week, the American Food and
BioTime reported that its subsidiary Asterias Biotherapeutics has reached an agreement with Cancer Research UK and Cancer Research Technology, the charity's development and commercialization arm, to conduct a clinical trial of Asterias' novel immunotherapy treatment AST-VAC2 in subjects with non-small cell lung cancer. We are delighted to partner..
Avedro Inc., a Boston- based ophthalmic medical device and pharmaceutical company announces today that it resubmitted its New Drug Application for riboflavin ophthalmic solution/ KXL System to the U.S. The proposed indications of treatment of progressive keratoconus or corneal ectasia following refractive surgery were both granted orphan status
The R %7 ED positions that will relocate to the new center are currently based in California and Europe. Joining this unmatched biotech community is an important step, "said Ludwig Hantson, Ph.D., president of Baxter BioScience. x0D;. "Our new innovation center will increase R %7 ED collaboration and efficiency, connect us directly to a rich poo
BBK Worldwide said that its mobile app for patient and site engagement, My Clinical Study Buddy, is a finalist for a 2014 SCRIP Award, "Best Technological Development in Clinical Trials" category. Selected by a panel of esteemed judges, award winners will be announced at a ceremony in London on December 3. According to a company release, launched a
Brainsway Ltd. is pleased to report substantial improvement in OCD patients following Brainsway Deep TMS treatment in a clinical study held in Sheba Medical center, Tel Ha'Shomer, Israel. Joseph Zohar, who was the chairperson of the anxiety and OCD section of the World Psychiatric Association, included 41 OCD patients who did not respond adequate
Celgene said that the U.S. Food and Drug Administration has approved OTEZLA, the Company's oral, selective inhibitor of phosphodiesterase 4, for the treatment of patients with moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate. "OTEZLA offers a valuable treatment option for a spectrum of plaque psoriasis p
Celldex Therapeutics, Inc. announced today the publication of two papers highlighting early studies of glembatumumab vedotin in breast cancer and metastatic melanoma in the Journal of Clinical Oncology. The papers, " A Phase 1/ 2 Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients with Advanced Melanoma" and " A Phase 1/ 2 Stud
CSP-1103 has undergone Phase 2 testing in people with Mild Cognitive Impairment, and CereSpir is integrating the findings to finalize the Phase 3 clinical protocol in consultation with key opinion leaders in AD research and the U.S. Food and Drug Administration. He retired from Myrexis in 2011. Hobden earned his Bachelor's and Master's degrees in..
CIS Acquisition recently reported the execution of a definitive agreement with Delta Technology Holdings Limited, a China based company specializing in providing fine and specialty chemicals to end application markets including Automotive, Pharmaceutical, Agrochemical, Dye& Pigments, Aerospace, Ceramics, Coating-Printing and Food Additives by...
A clinical study published in the August 23, 2014 issue of The Lancet demonstrated that delivery of AFLURIA with the PharmaJet Needle-Free Injector compared favorably to traditional needle and syringe delivery. In the PharmaJet study, 89 percent of the people receiving the PharmaJet Needle-Free Injection reported they would choose to receive thi
ALEXANDRIA, Va., Sept. 30 Collegium Pharmaceutical, Canton, Massachusetts, has been assigned a patent developed by five co-inventors for "amper-resistant pharmaceutical compositions of opioids and other drugs." The co-inventors are Said Saim, New Milford, Connecticut, Alison B. Fleming, North Attleboro, Massachusetts, Jane C. Hirsh, Wellesley, Ma
?receiving the Orphan Drug Designation from the U.S. Food and Drug Administration for COTI-2 in the treatment of ovarian cancer; x0D;. ?commencing trading on the OTCQB venture stage marketplace in the United States under the symbol COTQF. x0D;. Wayne Danter, President and CEO.
CSL Behring announced that it is set to commence operations in its newly expanded facility now that the U.S. Food& Drug Administration has granted approval. The new facility will use the same state-of-the-art technology as CSL Behring's long-standing manufacturing center of excellence in Bern, Switzerland. CSL Behring's Executive Vice President G
CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced the initiation of a global Phase 2 b clinical trial evaluating aldoxorubicin compared to topotecan in subjects with extensive-stage small cell lung cancer who have relapsed or were refractory to prior chemotherapy.
DanDrit Biotech A/S, the subsidiary of DanDrit Biotech USA, Inc., a biotechnology company seeking to develop an approved vaccine for the treatment of colorectal cancer, signed a contract of collaboration with the University Hospital IRCCS "San Martino"- IST National Institute for Cancer Research known as the San Martino Hospital of Genoa.
Diamond BioPharm Ltd announce today the opening of a new satellite office at Cambridge Science Park. "We are delighted to be expanding into our new satellite office in Cambridge," said Dr Maureen Graham, Managing Director of Diamond BioPharm Ltd. "This move will allow us to continue to deliver an outstanding consulting service to our clients throu